Standard Chemotherapy Strategy Versus Changing Chemotherapy Strategy as to FDG-PET Response After 1st Cycle of Standard Chemotherapy for Advanced Non-small Cell Lung Cancer
Prospective, Open-label, Randomized phase II, single institution trial that compared
chemotherapy guided by traditional evaluation based on RECIST versus chemotherapy guided by
FDG-PET (metabolic) response.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
change in response rate
The usual response rate of GenexolPM/Cisplatin chemotherapy is 30-40%. This trial will assess whether the changing chemotherapy strategy using FDG-PET can increase response rate by 15%.
within 4 cycles
Sang-We Kim, MD
Asan Medical Center
South Korea: Institutional Review Board